Imipenem/Cilastatin Aptapharma (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to multiple penicillin‑binding proteins, causing cell lysis. Cilastatin is co‑administered to block renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its antibacterial activity in the bloodstream.

The prescribed dose is set by the treating physician based on the type and severity of infection, the patient’s renal function, body weight, and any relevant comorbidities. Dosage adjustments are especially important in patients with impaired kidney function.

Safety data in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and the necessary import documentation.

Imipenem/cilastatin offers a broad spectrum that includes many Gram‑negative, Gram‑positive and anaerobic organisms, similar to meropenem and ertapenem. Its unique combination with cilastatin protects the drug from renal degradation, allowing higher plasma concentrations, but it may have a higher seizure risk in patients with renal impairment compared with some other carbapenems.

The product must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling.

Imipenem/Cilastatin is supplied as a sterile powder for injection. It is reconstituted with a compatible diluent and administered intravenously, usually as a short infusion over 15‑30 minutes. The exact infusion rate and duration are determined by the prescribing clinician.

The most serious adverse events include seizures, especially in patients with renal dysfunction or high doses; severe hypersensitivity reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis, which can lead to life‑threatening diarrhea and colonic inflammation.

Patients with a known hypersensitivity to imipenem, cilastatin, other carbapenems, or any beta‑lactam antibiotics should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting drugs listed under major interactions.